Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;17(10):1076-1093.
doi: 10.1111/ddg.13956.

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs - Short version, Part 1

Affiliations

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs - Short version, Part 1

Vera Mahler et al. J Dtsch Dermatol Ges. 2019 Oct.

Abstract

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physicians, nursing staff as well as patient representatives. The systematic methodological approach and appraisal of evidence upon which the recommendations are based are outlined in a separate method report that also contains evidence tables. The guidelines address general aspects of patch testing as well as medicolegal issues. The recommendations given relate to topics such as the indication for patch testing, informed patient consent, as well as the choice of test substances, test chambers and test site, duration of exposure, reading times and interpretation of test reactions. Furthermore, recommendations are provided with respect to endogenous and exogenous factors, specific patient groups (children, pregnant women, immunosuppressed individuals) as well as possible risks and adverse events associated with patch testing using contact allergens. Note: This publication is part 1 of the short version of the S3 guidelines for "Epicutaneous patch testing using contact allergens and drugs" (registry no. 013 - 018; date: March 20, 2019; valid until December 31, 2021). Part 2 of the short version will be published in the next issue. The long version of these guidelines can be accessed at www.awmf.org. The method report is available as online publication (https://www.awmf.org/leitlinien/detail/ll/013-018.html) and contains the evidence tables in its appendix.

PubMed Disclaimer

References

    1. Schnuch A, Aberer W, Agathos M et al. [Performing patch testing with contact allergens]. J Dtsch Dermatol Ges 2008; 6: 770-5.
    1. Johansen JD, Aalto-Korte K, Agner T et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis 2015; 73: 195-221.
    1. Geier J, Krautheim A, Lessmann H. [Allergological diagnostics and current allergens in occupational dermatology]. Hautarzt 2009; 60: 708-17.
    1. Mahler V. Epikutantests mit patienteneigenen und zugelassenen Testsubstanzen. Der Deutsche Dermatologe 2013; 61: 295-301.
    1. Mahler V, Dickel H, Diepgen TL et al. Stellungnahme der Deutschen - Kontaktallergie-Gruppe (DKG) und der Deutschen Dermatologischen Gesellschaft (DDG) zu haftungsrechtlichen Konsequenzen bei der Epikutantestung mit patienteneigenem Material. J Dtsch Dermatol Ges 2017; 15: 202-4.

LinkOut - more resources